These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 23357134)

  • 41. New perspectives on the use of niacin in the treatment of lipid disorders.
    McKenney J
    Arch Intern Med; 2004 Apr; 164(7):697-705. PubMed ID: 15078639
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
    Carlson LA
    J Intern Med; 2005 Aug; 258(2):94-114. PubMed ID: 16018787
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
    Jacobson TA; Glickstein SB; Rowe JD; Soni PN
    J Clin Lipidol; 2012; 6(1):5-18. PubMed ID: 22264569
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Parhofer KG
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):414-7. PubMed ID: 16151973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    Brown BG; Zhao XQ
    Am J Cardiol; 2008 Apr; 101(8A):58B-62B. PubMed ID: 18375243
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of hyperlipidemia with combined niacin-statin regimens.
    Guyton JR; Capuzzi DM
    Am J Cardiol; 1998 Dec; 82(12A):82U-84U; discussion 85-86U. PubMed ID: 9915667
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pleiotropic effects of nicotinic acid: beyond high density lipoprotein cholesterol elevation.
    Florentin M; Liberopoulos EN; Kei A; Mikhailidis DP; Elisaf MS
    Curr Vasc Pharmacol; 2011 Jul; 9(4):385-400. PubMed ID: 21314635
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pleiotropic effects of niacin: Current possibilities for its clinical use.
    Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
    Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HM74a agonists: will they be the new generation of nicotinic acid?
    Martres P
    Curr Top Med Chem; 2009; 9(5):428-35. PubMed ID: 19519459
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical update on the use of niacin for the treatment of dyslipidemia.
    Berra K
    J Am Acad Nurse Pract; 2004 Dec; 16(12):526-34. PubMed ID: 15645997
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Niacin: the evidence, clinical use, and future directions.
    Villines TC; Kim AS; Gore RS; Taylor AJ
    Curr Atheroscler Rep; 2012 Feb; 14(1):49-59. PubMed ID: 22037771
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.
    Duke Med Health News; 2010 Aug; 16(8):1-2. PubMed ID: 20799416
    [No Abstract]   [Full Text] [Related]  

  • 55. Nicotinic acid: an old drug with a promising future.
    Bodor ET; Offermanns S
    Br J Pharmacol; 2008 Mar; 153 Suppl 1(Suppl 1):S68-75. PubMed ID: 18037924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
    O'Kane MJ; Trinick TR; Tynan MB; Trimble ER; Nicholls DP
    Br J Clin Pharmacol; 1992 Apr; 33(4):451-3. PubMed ID: 1576071
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Niacin in therapy].
    Nagalski A; Bryła J
    Postepy Hig Med Dosw (Online); 2007 May; 61():288-302. PubMed ID: 17554232
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How will new medications affect the lipoprotein apheresis situation in Germany?
    Parhofer KG
    Atheroscler Suppl; 2013 Jan; 14(1):71-2. PubMed ID: 23357144
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nicotinic acid: pharmacological effects and mechanisms of action.
    Gille A; Bodor ET; Ahmed K; Offermanns S
    Annu Rev Pharmacol Toxicol; 2008; 48():79-106. PubMed ID: 17705685
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment.
    Kolovou GD; Daskalova DC; Petropoulos II; Anagnostopoulou KK; Bilianou HI; Pilatis ND; Pavlidis AN; Cokkinos DV
    Am J Cardiol; 2003 Dec; 92(11):1339-42. PubMed ID: 14636917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.